Generated: August 17, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 070617
describes VERAPAMIL HYDROCHLORIDE
, which is a drug marketed by Glenmark Generics, Mylan, Luitpold, Actavis Elizabeth, Pliva, Sandoz, Watson Labs, Exela Pharma Scs Llc, Sun Pharm Inds Inc, Ivax Sub Teva Pharms, Marsam Pharms Llc, Hospira, Warner Chilcott, Abraxis Pharm, Intl Medication, Par Pharm, Cadila Pharms Ltd, Apotex Corp, Heritage Pharms Inc, Mutual Pharm, Bedford, Sun Pharm Inds, Solopak, and Smith And Nephew, and is included in fifty-four NDAs. It is available from thirty-six suppliers. Additional details are available on the VERAPAMIL HYDROCHLORIDE profile page.
The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Nov 12, 1985||TE:||RLD:||No|
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.